2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1890

Longitudinal Deep Learning on Electronic Health Record Data to Predict Future Rheumatoid Arthritis Disease Activity
Abstract Number: 1891

Patterns of Biosimilar Use in the Rheumatology Informatics System for Effectiveness (RISE) Registry
Abstract Number: 1892

Patient and Health System Characteristics Associated with Receipt of Disease Modifying Anti-Rheumatic Drugs in a National VA Sample
Abstract Number: 1893

Indoleamine-2,3-Dioxygenase in Murine and Human Systemic Lupus Erythematosus
Abstract Number: 1894

Baricitinib-Associated Changes in Type l Interferon Gene Signature during a 24-Week Phase-2 Clinical SLE Trial
Abstract Number: 1895

Marked Immune Cell Subset Changes in Refractory Lupus Patients in a Phase I Trial of Allogenic Mesenchymal Stem Cells
Abstract Number: 1896

Lupus Keratinocytes Exhibit Skewed Interferon Responses and Dysregulation of a Novel Regulator of Interferon Signaling
Abstract Number: 1897

Single Cell RNA Expression in Lupus Nephritis Comparing African-American and Caucasian Patients Identifies Differential Expression of Interferon Pathway
Abstract Number: 1898

Type I Interferon-Induced Proteins May Facilitate the Occurrence of Long QT Syndrome (LQTS) in Parallel with Anti-Ro/SSA and Anti-Ro52/TRIM21 Antibody Levels in Patients with Systemic Lupus Erythematous (SLE): A Bench to Bedside Approach
Abstract Number: 1899

Down-Regulation of RNA Processing Protein CFIm25 Amplifies Skin Fibrosis By up-Regulating Pro-Fibrotic Transcripts/Proteins in Systemic Sclerosis
Abstract Number: 1900

FGFR3/ FGF9 Regulates the Activity of Profibrotic Cytokine and Growth Factor Pathways to Drive Fibroblast Activation and Tissue Fibrosis in Systemic Sclerosis
Abstract Number: 1901

Reduced SPAG17 Expression Links Dysfunctional Cilia, Morphogen Signaling Activation and Multiple Organ Fibrosis: Novel Target for Systemic Sclerosis
Abstract Number: 1902

Pathogenic and Therapeutic Modulation of Activating Epigenetic Memory at a Novel Enhancer for TGFβ2 in Systemic Sclerosis
Abstract Number: 1903

Molecular Analysis of a Skin Equivalent Tissue Culture Model System of Systemic Sclerosis Using RNA Sequencing, Epigenetic Assays, Histology, and Immunoassays
Abstract Number: 1904

Orphan Nuclear Receptor Rorα Is a Key Regulator of Tgfβ- and WNT-Signaling in Fibrotic Diseases

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].